Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy
Here we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at all doses after 18 months ...
May 14, 2026 07:32 AM EDT R&D Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy Max Gelman Senior Editor Here we go again? Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not meet its primary endpoint in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that